Frank Miller

List of Publications by Year
in descending order

26 papers	463 citations	759233 12 h-index	713466 21 g-index
27 all docs	27 docs citations	27 times ranked	468 citing authors

#	Article	IF	Citations
1	A Simulation Study to Compare New Adaptive Doseâ€“Ranging Designs. Statistics in Biopharmaceutical Research, 2010, 2, 487-512.	0.8	58
2	Optimal Designs for Estimating the Interesting Part of a Dose-Effect Curve. Journal of Biopharmaceutical Statistics, 2007, 17, 1097-1115.	0.8	49
3	Experiences with an adaptive design for a dose-finding study in patients with osteoarthritis. Contemporary Clinical Trials, 2014, 37, 189-199.	1.8	47
4	Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendations. White Paper of the PhRMA Working Group on Adaptive Dose-Ranging Studies. Statistics in Biopharmaceutical Research, 2010, 2, 435-454.	0.8	40
5	Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov. Orphanet Journal of Rare Diseases, 2017, 12, 44.	2.7	31
6	Recent advances in methodology for clinical trials in small populations: the InSPiRe project. Orphanet Journal of Rare Diseases, 2018, 13, 186.	2.7	30
7	Variance Estimation in Clinical Studies with Interim Sample Size Reestimation. Biometrics, 2005, 61, 355-361.	1.4	28
8	Determination of the optimal sample size for a clinical trial accounting for the population size. Biometrical Journal, 2017, 59, 609-625.	1.0	27
9	Decision-theoretic designs for small trials and pilot studies: A review. Statistical Methods in Medical Research, 2016, 25, 1022-1038.	1.5	20
10	A Seamless Phase II/III Design with Sample-Size Re-Estimation. Journal of Biopharmaceutical Statistics, 2009, 19, 595-609.	0.8	16
11	Approaches to sample size calculation for clinical trials in rare diseases. Pharmaceutical Statistics, 2018, 17, 214-230.	1.3	16
12	Blinded Continuous Monitoring of Nuisance Parameters in Clinical Trials. Journal of the Royal Statistical Society Series C: Applied Statistics, 2012, 61, 601-618.	1.0	13
13	Value of information methods to design a clinical trial in a small population to optimise a health economic utility function. BMC Medical Research Methodology, 2018, 18, 20.	3.1	12
14	A decision theoretical modeling for Phase III investments and drug licensing. Journal of Biopharmaceutical Statistics, 2018, 28, 698-721.	0.8	10
15	Adaptive doseâ€finding: Proof of concept with type I error control. Biometrical Journal, 2010, 52, 577-589.	1.0	9
16	Perspective on adaptive designs: 4 years European Medicines Agency reflection paper, 1 year draft US FDA guidance â€“ where are we now?. Clinical Investigation, 2012, 2, 235-240.	0.0	9
17	Early phase drug development for treatment of chronic pain â€” Options for clinical trial and program design. Contemporary Clinical Trials, 2012, 33, 689-699.	1.8	9
18	Estimation after blinded sample size reassessment. Statistical Methods in Medical Research, 2018, 27, 1830-1846.	1.5	8

#	Article	IF	Citations
19	Discrimination with unidimensional and multidimensional item response theory models for educational data. Communications in Statistics Part B: Simulation and Computation, 2022, 51, 2992-3012.	1.2	8
20	Conditional Estimation in Two-Stage Adaptive Designs. Biometrics, 2017, 73, 895-904.	1.4	6
21	Implementation of maximin efficient designs in doseâ€finding studies. Pharmaceutical Statistics, 2015, 14, 63-73.	1.3	5
22	Improving Dose-Finding. , 2010, , 10-1-10-23.		5
23	Optimal Item Calibration for Computerized Achievement Tests. Psychometrika, 2019, 84, 1101-1128.	2.1	3
24	Optimal doseâ€finding for efficacyâ€“safety models. Biometrical Journal, 2021, 63, 1185-1201.	1.0	2
25	An exchange algorithm for optimal calibration of items in computerized achievement tests. Computational Statistics and Data Analysis, 2021, 157, 107177.	1.2	1
26	Efficient Estimation of Mean Ability Growth Using Vertical Scaling. Applied Measurement in Education, 0, , 1-16.	1.1	1